{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-023068","form_type":"8-K","ticker":"ATXI","cik":"0001644963","company_name":"AVENUE THERAPEUTICS, INC.","filed_at":"2023-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.665846+00:00","generated_at":"2026-06-11T17:51:45.290991+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Avenue Therapeutics Q2 net loss $4.0M; first AJ201 patient dosed, FDA agrees on tramadol Phase 3 design","bullets":["Net loss of $4.0M ($0.52 per share) vs $0.6M ($0.41) in Q2 2022; cash $1.6M down from $6.7M at year-end 2022.","First patient dosed in Phase 1b/2a trial of AJ201 for SBMA; topline data expected H1 2024.","BAER-101 preclinical results show full seizure suppression at 0.3 mg/kg in GAERS model; Phase 2a planned for 2024.","FDA alignment on Phase 3 safety study design for IV tramadol; subject to financing, company aims to start soon.","R&D expense surged to $3.0M from $0.2M; G&A $0.9M vs $0.5M, reflecting clinical progress."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-023068","json":"https://secwatch.observer/filing/0001437749-23-023068.json","markdown":"https://secwatch.observer/filing/0001437749-23-023068.md","text":"https://secwatch.observer/filing/0001437749-23-023068.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1644963/000143774923023068/0001437749-23-023068-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1644963/000143774923023068/atxi20230530_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T17:51:45.290991+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5aa139d0377c1241af1716dd618850d2591293cb","claim":"AVENUE THERAPEUTICS, INC. reported second quarter ended June 30, 2023 results: net income Net loss attributable to common stockholders for the second quarter of 2023 was $4.0 million, or $0.52 per share, EPS $0.52 per share.","evidence_excerpt":"On August 10, 2023, Avenue Therapeutics, Inc. (the “Company” or “Avenue”) issued a press release to provide a corporate update and to announce its financial results for the three months ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1644963/000143774923023068/0001437749-23-023068-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter ended June 30, 2023"},{"label":"Net income","value":"Net loss attributable to common stockholders for the second quarter of 2023 was $4.0 million, or $0.52 per share"},{"label":"EPS","value":"$0.52 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}